Inventor
SU UI LEE
Inventor
KR
Overview
Patents· 3 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes20%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
A23KFodder13%
A23LFoods, foodstuffs or non-alcoholic beverages, not otherwise provided for13%
A23VIndexing scheme relating to foods, foodstuffs or non-alcoholic beverages and lactic or propionic acid bacteria used in foodstuffs or food preparation13%
C07KPeptides7%
C12NMicroorganisms or enzymes7%
G01NInvestigating or analysing materials by determining their chemical or physical properties7%
PatentTitleYear
12,390,505Composition for preventing or treating obesity or diabetes, comprising acanthopanax senticosus extract and garcinia cambogia extract or compound isolated therefrom202511,707,486Natural killer cell expressing anti-cotinine chimeric antigen receptor202311,135,193Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021Patents assigned to ENZYCHEM LIFESCIENCES CORP (1)· patent assignee history
2021Patents assigned to KOREA RES INSTITUTE OF BIO SCIENCE AND BIOTECHNOLOGY (1)· patent assignee history
2021–2025Based in KR· patent location history
2023–2025Patents assigned to KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY (2)· patent assignee history
2023Patents assigned to SEOUL NAT UNIV R&DB FOUNDATION (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY | 2 | 2023–2025 |
| ENZYCHEM LIFESCIENCES CORP | 1 | 2021 |
| KOREA RES INSTITUTE OF BIO SCIENCE AND BIOTECHNOLOGY | 1 | 2021 |
| SEOUL NAT UNIV R&DB FOUNDATION | 1 | 2023 |
Locations
| Location | Patents | Span |
|---|---|---|
| KR | 3 | 2021–2025 |